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Abstract
Purpose Methylglyoxal, a by-product of glycolysis and a precursor in the formation of advanced glycation end-products, is
significantly elevated in the diabetic myocardium. Therefore, we sought to investigate the mitochondria-targeted methylglyoxal
scavenger, MitoGamide, in an experimental model of spontaneous diabetic cardiomyopathy.
Methods Male 6-week-old Akita or wild type mice received daily oral gavage of MitoGamide or vehicle for 10 weeks. Several
morphological and systemic parameters were assessed, as well as cardiac function by echocardiography.
Results Akita mice were smaller in size than wild type counterparts in terms of body weight and tibial length. Akita mice
exhibited elevated blood glucose and glycated haemoglobin. Total heart and individual ventricles were all smaller in Akita mice.
None of the aforementioned parameters was impacted by MitoGamide treatment. Echocardiographic analysis confirmed that
cardiac dimensions were smaller in Akita hearts. Diastolic dysfunction was evident in Akita mice, and notably, MitoGamide
treatment preferentially improved several of these markers, including e′/a′ ratio and E/e′ ratio.
Conclusions Our findings suggest that MitoGamide, a novel mitochondria-targeted approach, offers cardioprotection in exper-
imental diabetes and therefore may offer therapeutic potential for the treatment of cardiomyopathy in patients with diabetes.
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Introduction
Diabetes is a well-known risk factor for the development of
cardiovascular diseases, pertinent since the global incidence
of diabetes is set to exceed 642 million by 2040 [1].
Cardiovascular disease is arguably the most important com-
plication of diabetes, increasing heart failure risk 2.4-fold in
diabetic men and 5-fold in diabetic women [2, 3], but also
accounting for the majority of healthcare costs and significant-
ly reducing life expectancy. In one study, the 1-year mortality
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of heart failure was 30% in people with diabetes, about 1.5-
fold greater than in those without diabetes [4]. Diabetic heart
disease exists across a range of aetiologies, including coronary
heart disease, diabetic cardiomyopathy and heart failure.
Diabetes can expedite or even initiate changes in each disease
scenario. For example, diabetes accelerates the progression of
atherosclerosis in coronary arteries, exacerbates small vessel
disease leading to increased cardiac load, compromised cardi-
ac performance and eventual heart failure, and promotes det-
rimental cardiac remodelling characteristic of diabetic cardio-
myopathy, including cardiomyocyte hypertrophy, elevated in-
terstitial fibrosis and cardiomyocyte apoptosis [5].
The heart is the most metabolically active organ in the body
and possesses the highest amount of mitochondria, the pow-
erhouses of the cell [6]. The high myocardial mitochondria
content is absolutely critical in order to provide the tremen-
dous amount of energy needed to maintain cardiac contraction
and relaxation. In fact, despite the heart accounting for only
0.5% of body weight, it is responsible for 8% of ATP con-
sumption [6]. Given that tissues with a greater metabolic de-
mand are more susceptible to chronic complications, mito-
chondrial impairment has been implicated in the pathophysi-
ology of diabetic heart disease [7]. Methylglyoxal, a by-
product of glycolysis and a reactive carbonyl species, is sig-
nificantly elevated in diabetes and reacts with arginine and
lysine residues to form irreversible carbonyl adducts [8].
Importantly, mitochondrial proteins are major targets of
dicarbonyl glycation and are associated with increased reac-
tive oxidative species formation and subsequent cardiac dam-
age [9]. We hypothesise that the metabolic derangements in-
dicative of diabetes, and subsequent dicarbonyl glycation,
play a role in the development of diabetic cardiomyopathy.
MitoGamide is an amide analogue of MitoG [10], which has
been used to assess the accumulation of glyoxal and
methylglyoxal in the mitochondria of the Akita mouse model
of diabetes in vivo [10]. The two molecules share the
methylglyoxal-scavenging diaminoaryl group and the
mitochondria-targeting triphenylphosphonium moiety, but
MitoGamide incorporates an amide link to facilitate synthesis
and limit autooxidation. Therefore, in the present study we
sought to investigate the cardioprotective potential of the nov-
el mitochondria-targeted methylglyoxal scavenger,
MitoGamide (Fig. 1a), in the setting of experimental diabetic
cardiomyopathy.
Methods
Animals
All activities involving the use of animals for research were
approved by the Alfred Medical Research Education Precinct
(AMREP) Animal Ethics Committee and were conducted
according to guidelines of the National Health and Medical
Research Council of Australia for animal experimentation.
For all experiments, we have included flow charts for the
reporting of animal use and analysis in preclinical studies
(Supplementary Fig. 1). The main aim of this study was to
investigate the impact of MitoGamide treatment on cardiac
function in an experimental model of diabetic cardiomyopa-
thy. Accordingly, our primary endpoint was impact of
MitoGamide treatment on e′/a′ ratio and E/A ratio, markers
of LV diastolic function. Diabetic Akita mice (C57BL/6J-
Ins2Akita; heterozygous for the mutation) and their wild type
(WT) counterparts were purchased from the Jackson
Laboratory, bred at the AMREP Animal Centre and main-
tained under a 12-h light/dark cycle. At 6 weeks of age, male
littermates of both genotypes were assigned to receive either
vehicle (10% ethanol in water), orMitoGamide (10 mg/kg) by
daily oral gavage. Saphenous vein nonfasted blood glucose
measurements (BHigh^ measurements recorded at
33.3 mmol/L; ACCU-CHEK glucometer, Roche) and body
weights were recorded on a weekly basis as part of animal
monitoring. Glycated haemoglobin (HbA1c) was measured
1 week prior to study end using the Cobas B 101 system
(Roche). Plasma insulin levels were measured using Mouse
Ultrasensitive Insulin ELISA kit, as per manufacturer’s in-
structions (80-INSMSU-E01, ALPCO). At study end, animals
received an overdose of sodium pentobarbital (80 mg/kg i.p.)
prior to rapid excision and collection of hearts.
Echocardiography
Echocardiography was performed in anaesthetised mice (ke-
tamine/xylazine/atropine: 100/10/0.96 mg/kg i.p. at study
endpoint utilising a Philips iE33 ultrasound machine with
15-MHz linear (M-mode) and 12-MHz sector (Doppler) trans-
ducer. LV posterior wall (PWd) thickness, LV chamber di-
mensions and fractional shortening were assessed from M-
mode imaging. LV filling was assessed using transmitral
Doppler flow; the ratio of early (E) and atrial (A) blood flow
velocities (E/A ratio) and E-wave deceleration time were mea-
sured. Tissue Doppler echocardiography was used to assess
the ratio of e′ velocity and a′ velocity (e′/a′ ratio).
Statistical Analysis
Data were analysed with GraphPad Prism 8.01 statistical soft-
ware package. All data are presented as mean ± standard error
of the mean (SEM). Two-way analysis of variance (ANOVA)
was used to detect main effects for genotype (WT vs Akita)
and treatment (vehicle vs MitoGamide), followed by Tukey’s
post hoc test to analyse the differences between individual
experimental groups. Statistical significance was considered
at P < 0.05.
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Results
Characterisation of Diabetes and Cardiac Dimensions
Male Akita or wild type mice at 6 weeks of age received daily
oral gavage of MitoGamide or vehicle for a duration of
10 weeks (Fig. 1b). At study end, body weight and tibial
length were smaller in diabetic mice compared with wild type
(Table 1), consistent with previous reports using this model
[11]. Blood glucose and glycated haemoglobin levels were
significantly elevated in Akita mice (Table 1). Plasma insulin
levels were reduced in Akita mice compared with wild type
mice (Table 1).MitoGamide treatment had no effect compared
with vehicle treatment on the aforementioned measures. Heart
weight normalised to tibial length was significantly reduced in
the Akita vehicle-treated mice compared with wild type
vehicle-treated mice (Table 1). When LV weight and RV
weight were considered independently, they mirrored the re-
sults seen in total heart weight (Table 1).
Cardiac Function
TissueDoppler imaging showed a significant decrease in peak e′
wave velocity in Akita vehicle-treated mice compared with
wild-type vehicle-treated mice (Fig. 1c), an effect attenuated
by MitoGamide treatment. There was no difference between
groups in terms of peak a′ velocity (Fig. 1c). This translated into
a significant decrease in e′/a′ ratio in the Akita vehicle-treated
mice that was attenuated following MitoGamide treatment
(Fig. 1d). There was a clear trend evident that MitoGamide
treatment impacted the prolongation of deceleration time ob-
served in vehicle-treated Akita mice (P = 0.07, Fig. 1e). E/e′
ratio was reduced in MitoGamide-treated Akita mice compared
with Akita vehicle mice (Fig. 1f). Doppler echocardiographic
assessment of LV diastolic function indicated a significant de-
crease in E-wave velocity in Akita mice (Fig. 1g). However,
there was no difference between groups in terms of peakAwave
velocity (Fig. 1g). This translated to a significant reduction in
E/A ratio, indicative of LV diastolic dysfunction (Fig. 1h); this
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Fig. 1 MitoGamide treatment attenuates LV diastolic dysfunction in
Akita mice. a The structure of MitoGamide. b Overview of
experimental protocol. Tissue Doppler echocardiography was used to
derive c peak e′ and peak a′ velocity, and d e′/a′ ratio. Doppler
echocardiography was used to derive e deceleration time. f E/e′ ratio g
peak E and peak A wave velocity, and h E/A ratio. i Representative
images of Doppler and tissue Doppler echocardiography. Data are
presented as mean ± SEM. n = 8–13 per group. *P < 0.05, **P < 0.01,
****P < 0.0001. Two-wayANOVA followed by Tukey’s post hoc test. V,
vehicle; MG, MitoGamide; WT, wild type
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impairment was not evident in MitoGamide-treated Akita mice.
Representative images of tissue Doppler imaging and Doppler
imaging are provided in Fig. 1i. These findings reveal that
MitoGamide treatment in diabetic mice protects against the de-
velopment of impaired ventricular relaxation.
LV M-mode echocardiographic structure and systolic func-
tion were significantly different between wild type and Akita
mice, indicated by a reduction in LV end-systolic and end-
diastolic dimensions, including Ex-LVEDD, AWd, PWd and
LVESD (Table 1). Fractional shortening was significantly ele-
vated inAkitamice comparedwith age-matchedwild typemice.
Importantly, MitoGamide treatment exerted no impact on echo-
cardiographic parameters of LV structure and M-mode-derived
systolic function, and heart rate remained unchanged, between
all groups for echocardiographic measurements (Table 1).
Discussion
The key finding of this study is the novel compound
MitoGamide, an amide variant of MitoG [10] and
mitochondria-targeted methylglyoxal scavenger, offers
cardioprotection in the Akita mouse model of spontaneous
experimental diabetes. MitoGamide treatment exhibited no
impact on the underlying diabetes phenotype; however,
MitoGamide preferentially improved several markers of LV
diastolic dysfunction in diabetic mice. Given the well-
established link between the increased global burden of dia-
betes and an increased risk of clinical heart failure [2], identi-
fication of new pharmacological treatment strategies designed
specifically to target the underlying metabolic perturbations in
disease pathogenesis is particularly timely [3].
Diabetes is a complex metabolic disease characterised pri-
marily by hyperglycaemia but with many other interacting
factors that lead to a broad range of complications, including
diabetic heart disease. The rationale for this study was based
on reports that methylglyoxal levels are elevated in diabetes
[8, 12], as the enzyme responsible for the removal of
methylglyoxal, glyoxalase 1, becomes saturated.
Accumulating levels of methylglyoxal provide an important
precursor for the nonenzymatic glycation of proteins, affecting
the structure and function of proteins and ultimately affecting
intracellular events [10]. Mitochondrial proteins are major tar-
gets of dicarbonyl glycation and are associated with increased
Table 1 Systemic characteristics,
organ morphology and
echocardiographic analysis of
systolic heart function in
anaesthetised wild type and Akita
mice treated with MitoGamide or
vehicle
Wild type Akita
Vehicle MitoGamide Vehicle MitoGamide
Systemic characteristics/organ morphology
n 14 15 14 12
Body weight (g) 29.9 ± 1.2 28.5 ± 0.5 22.8 ± 0.9**** 23.7 ± 0.7**
Tibial length (mm) 17.3 ± 0.1 17.1 ± 0.2 16.7 ± 0.1* 16.4 ± 0.1**
Blood glucose (mmol/L) 10.8 ± 0.6 11.7 ± 0.7 33.0 ± 0.0**** 32.6 ± 0.4****
HbA1c (%) 4.60 ± 0.17 4.83 ± 0.16 13.1 ± 0.35**** 13.3 ± 0.26****
Plasma insulin (ng/mL) 0.89 ± 0.04 0.92 ± 0.07 0.75 ± 0.01* 0.78 ± 0.02
Heart weight/tibial length (mg/mm) 9.19 ± 0.42 8.26 ± 0.33 7.02 ± 0.13**** 7.72 ± 0.33
LV/tibial length (mg/mm) 6.18 ± 0.27 5.57 ± 0.19 4.50 ± 0.10**** 5.05 ± 0.16
RV/tibial length (mg/mm) 1.64 ± 0.09 1.54 ± 0.08 1.25 ± 0.06** 1.30 ± 0.07
LV function
n 12 13 9 10
Heart rate (bpm) 399 ± 17 418 ± 11 381 ± 10 385 ± 15
Ex-LVEDD (mm) 5.75 ± 0.11 5.51 ± 0.09 5.19 ± 0.05** 5.31 ± 0.09
AWd (mm) 0.67 ± 0.02 0.67 ± 0.01 0.60 ± 0.02* 0.61 ± 0.01*
LVEDD (mm) 4.40 ± 0.12 4.19 ± 0.10 4.01 ± 0.08 4.09 ± 0.12
PWd (mm) 0.68 ± 0.02 0.68 ± 0.02 0.60 ± 0.01*** 0.63 ± 0.01
LVESD (mm) 3.15 ± 0.08 2.96 ± 0.10 2.55 ± 0.09*** 2.58 ± 0.09*
Fractional shortening (%) 28.3 ± 0.5 29.5 ± 1.0 36.5 ± 1.6**** 37.0 ± 0.8****
Estimated LV mass (mg) 112 ± 5 101 ± 4 81 ± 2*** 87 ± 3
Estimated LV mass/BW (mg/g) 3.76 ± 0.19 3.53 ± 0.10 3.68 ± 0.14 3.74 ± 0.21
Estimated LV mass/TL (mg/mm) 6.47 ± 0.29 5.90 ± 0.24 4.84 ± 0.13*** 5.29 ± 0.19
Data are presented as mean ± SEM and analysed by two-way ANOVA followed by Tukey’s post hoc test.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs corresponding wildtype. Ex-LVEDD, external LV end
diastolic dimension; Awd, anterior wall diastolic thickness; LVEDD, LVend diastolic dimension; PWd, posterior
wall diastolic thickness; LVESD, LV end systolic dimension; BW, body weight; TL, tibial length
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reactive oxidation species formation and subsequent cardiac
damage [9]. Methylglyoxal affects several cellular functions
such as insulin signalling, mitochondrial respiration and gly-
colysis, whilst high-dose methylglyoxal therapy has been
highlighted as a potential therapeutic option in cancer settings
due to its cytotoxic effects [13]. Importantly, several
mitochondria-targeted antioxidants confer beneficial improve-
ments on cardiac function, although, to our knowledge, this is
the first study to investigate the effect of a mitochondrial-
targeted approach to reduce methylglyoxal levels in the dia-
betic heart.
To specifically address the potential for selectively
targeting mitochondrial methylglyoxal in the diabetic heart,
we chose to employ an established genetic model of maturity
onset diabetes of the young (MODY)4 and insulin insufficien-
cy using the Ins2WT/C96Y Akita mouse model. Although this
model may not be as clinically relevant as one that mimics the
more prevalent type 2 diabetes, utilising the Akita mouse
model avoids the additional confounding factors of obesity
and impaired leptin signalling evident in the most widely ac-
cepted mouse model of type 2 diabetes that manifests detect-
able cardiac dysfunction, the spontaneously diabetic db/db
mouse. Importantly, the Akita mouse model shares common
structural and functional features of clinical diabetic cardio-
myopathy and was therefore an appropriate choice for this
study. Although the pathogenesis of type 1 and type 2 diabetes
are distinct at the systemic level, the changes that occur in the
myocardium, and in particular the cardiac mitochondria, in
both forms of diabetes, share numerous similarities [7].
The early stages of diabetic cardiomyopathy are commonly
characterised by LV diastolic dysfunction and ventricular hy-
pertrophy, and in later stages by LV systolic dysfunction
progressing to decompensated heart failure [3, 5]. Consistent
with previous studies [14], our data confirm the presence of
LV diastolic dysfunction at 16 weeks of age in Akita mice.
Evaluation of both Doppler flow and tissue Doppler echocar-
diography revealed that 16 weeks of hyperglycaemia con-
ferred a reduction in e′/a′ ratio and E/A ratio, and a prolonga-
tion of deceleration time (Fig. 1). Importantly, myocardial
function of diabetic mice treated with MitoGamide for the
final 10 weeks of the study exhibited significant improve-
ments in e′/a′ ratio and E/e′ ratio and a non-significant im-
provement in E/A ratio (P = 0.16, Fig. 1), indicating that
MitoGamide offers cardioprotection in this experimental
model of diabetic cardiomyopathy. These reports are consis-
tent with previous reports that overexpression of glyoxalase 1,
the enzyme responsible for removing accumulating levels of
methylglyoxal, in a type 1 model of diabetic cardiomyopathy,
delayed and limited impairment in cardiac function [14]. At
the time point in which cardiac function was assessed in our
study, it is important to note that LV end-systolic and end-
diastolic dimensions were smaller in the Akita mice and there
was a significantly higher fractional shortening (Table 1).
These findings are consistent with other studies using this
model [15] and likely explained by the genetic nature of the
model, where Akita mice exhibit smaller body weight, tibial
length, heart and LV size when normalised to tibial length
(Table 1). The phenotype of the Akita mouse hence precludes
any inference regarding the presence or absence of LV systolic
dysfunction in this model; however, MitoGamide treatment
did not affect any of these parameters (Table 1).
Future directions, based on the findings outlined in this
short communication, will likely include substantiating the
role of MitoGamide in the more clinically relevant setting of
type 2 diabetes. Emphasis can then be placed on understand-
ing the role, if any, of MitoGamide on mitochondrial function
and oxidative stress. Furthermore, the current studies only
describe the ability of MitoGamide to prevent the develop-
ment of cardiac dysfunction, whereas future studies will de-
termine the ability of MitoGamide to protect against
established cardiac dysfunction, the most likely clinical sce-
nario. This will include the use of serial echocardiography.
Indeed, it is likely any novel treatment option that has efficacy
in terms of cardiac function will supplement (not replace)
current therapeutic options in the management of disease.
Further, one limitation of the current study was that it only
included male mice. Future studies will determine if therapeu-
tic intervention is effective in both male and female mice.
Taken together, our data indicate that MitoGamide treat-
ment confers cardioprotection in an experimental model of
diabetic cardiomyopathy, and although further work is clearly
required to elucidate the underlying mechanisms, our findings
highlight a novel mitochondria-targeted approach that may
prevent the onset, or slow the progression, of diabetic
cardiomyopathy.
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